Di seguito l'elenco completo dei nostri comunicati stampa (pagina 26 di 28):
EMA PRAC mandates DHPCs and product information updates for desogestrel, etonogestrel contraceptives and Litfulo. MAHs must act on communication plans now.
India tightens controls on high-alcohol medicinal formulations. QA directors and regulatory leads must review labelling, distribution, and dossier requirements now.
FDA approves IV and subcutaneous pembrolizumab each with enfortumab vedotin-ejfv for muscle invasive bladder cancer. Key manufacturing and QA implications.
AB Science discontinues masitinib studies in MCAS, mastocytosis, and MS to prioritize AB8939 AML and masitinib ALS Phase 3 programs. Closeout and amendment obligations follow.
FDA approves Sanofi's subcutaneous isatuximab-irfc via CirCLIQ on-body device for multiple myeloma. Key GMP and combination product implications for fill-finish teams.
Elevar Therapeutics receives FDA CRL for rivoceranib-camrelizumab HCC NDA due to cGMP manufacturing site deficiencies. Clinical data was not in question.
FDA mandated a GBS warning for Pfizer's ABRYSVO and GSK's Arexvy in January 2025. Key post-approval labeling and biologics lifecycle management implications for QA and regulatory teams.
FDA's final guidance on pre-submission facility correspondence for priority ANDAs under GDUFA III sets a concrete framework for review goal assignment. Key read for regulatory affairs teams.
Gennova Biopharma divests its mRNA platform to Immunoscript for Rs. 139.5 crore amid post-COVID manufacturing cost pressures and regulatory complexity.
NATCO Pharma's Rs. 1,069 crore stake increase in Adcock Ingram triggers dual SAHPRA-CDSCO compliance obligations for manufacturing and QA teams.
Sun Pharma's Rs. 33,500 crore cumulative R&D spend drives specialty pipeline growth with major implications for GMP manufacturing, tech transfer, and global regulatory submissions.
Health Canada issues NOC for CLINUVEL's SCENESSE (afamelanotide) in EPP. Post-marketing data from three prior approvals anchored the Canadian submission.
Azurity Pharmaceuticals acquires Matinas BioPharma's LNC drug delivery platform and MAT2203 for up to $21.5M. Key GMP and regulatory transfer implications for pharma ops leaders.
Sun Pharma joins the 2026 S&P Dow Jones Best-in-Class World Index among 317 global companies for sustainability leadership.
Eupraxia Pharmaceuticals names new EVP Technical Ops and EVP R&D as it prepares EP104GI for Phase 3 and restructures to Vancouver-Seattle hubs.
Acentra Health appoints Michael Kingston as Chief Digital & Information Officer to drive AI, cybersecurity, and digital transformation across healthcare solutions.
Cue Biopharma appoints Dominic Borie as CMO and R&D Head to lead its growing immunology and autoimmune disease pipeline.
Pliant Therapeutics appoints Flavia Borellini and Robert Iannone to its board, adding extensive oncology leadership expertise.
Geron appoints biopharma veteran Chinmaya Rath as Chief Business Officer to support growth in hematology and oncology.
Roche launches automated cobas HDV test to detect and monitor Hepatitis D Virus, expanding its molecular diagnostics portfolio.
Roche's Gazyva receives FDA Priority Review for primary membranous nephropathy after positive Phase III MAJESTY trial results.
Roche's Gazyva receives FDA Priority Review for primary membranous nephropathy after positive Phase III MAJESTY trial results.
Humacyte appoints two leading nephrologists as advisors to support commercial launch of ATEV for hemodialysis access.
Biogen reports positive Phase 2 results for diranersen, a tau-targeting therapy for Alzheimer's, and plans Phase 3 trials.
Spur Therapeutics announces a leadership transition: CEO Michael Parini becomes Board Chair as Dr. Henning Stennicke steps up as COO.
ORIC Pharmaceuticals launches Phase 3 Himalayas-1 trial of rinzimetostat with Bayer's darolutamide for advanced prostate cancer.
Celcuity's REVTORPYK gains FDA approval for HR+/HER2-negative, PIK3CA wild-type advanced or metastatic breast cancer.
Silo Pharma's QwikAgents joins AMD's AI Developer Program to accelerate its AI agent platform development.
MBX Biosciences names Hoerter CEO and Smither CFO ahead of Phase 3 canvuparatide launch and three key H2 2026 pipeline milestones.
Mesoblast hits 300-patient enrollment in Phase 3 trial of rexlemestrocel-L for chronic low back pain, targeting top-line data and BLA filing in mid-2027.
Attovia Therapeutics appoints John Smither to its Board as Audit Committee Chair; co-founder Dr. Yuling Luo steps down.
NewcelX secures Brazilian patent protecting NCEL-101 manufacturing tech for its type 1 diabetes cell therapy.
Rectify Pharmaceuticals appoints Constantine Chinoporos as Executive Chairman as RTY-406 enters Phase 1.
European Commission approves Novo Nordisk's oral Wegovy pill for chronic weight management in the EU.
RadioMedix appoints former Lantheus CEO Brian Markison to its Board as independent director.
Celldex Therapeutics CFO Sam Martin to retire in 2027; company begins successor search.
Mobia Medical appoints medtech veteran Reza Zadno, former PROCEPT BioRobotics CEO, to its Board.
Gyre Therapeutics strengthens its Board with three new directors bringing scientific and global leadership expertise.
Jasper Therapeutics closes Kira Pharmaceuticals deal and raises $132M to fund its immunology pipeline.
Novartis's Fabhalta receives full FDA approval to slow kidney function decline in adults with IgA nephropathy, backed by Phase III trial data.
Clearmind Medicine's intranasal MEAI formulation shows improved nasal tissue retention in an ex vivo study for Alcohol Use Disorder treatment.
Arcutis Biotherapeutics appoints Mirum Pharmaceuticals CEO Chris Peetz to its Board to support ZORYVE franchise growth and pipeline expansion.
Rinascera Therapeutics launches with backing from Double Point Ventures to advance RIN-001 and RIN-002 for rare genetic skin diseases.
Amneal Pharmaceuticals wins FDA approval for new iohexol injection strengths and vial sizes, expanding its contrast imaging portfolio.
Plus Therapeutics partners with Genomic Testing Cooperative to add DNA and RNA profiling to its CNSide CNS oncology platform.
Diagonal Therapeutics doses first patient in its Phase 1/2 DIAMOND trial of DIAG723 for hereditary hemorrhagic telangiectasia.
Angelini Pharma completes its acquisition of Catalyst Pharmaceuticals, expanding its global brain health and rare disease business.
RxSight appoints Aziz Mottiwala as President and CEO, succeeding Ron Kurtz, who remains Chief Medical Officer.
Cytosurge appoints biotech executive Luba Greenwood to its Board to support its AI-driven drug discovery platform.
Emcure's Poviztra® (semaglutide) wins CDSCO approval for MASH, India's first approved GLP-1 for the liver disease.
Positron secures three new 64-slice PET-CT orders from nuclear cardiologists, each with a multi-year service agreement.
Conceivable Life Sciences names a President and SVP ahead of AURA's U.S. launch with IVI RMA Global.
Meliora Healthcare adds orthopedic surgeon Dr. Scott Thompson, expanding sports medicine and joint care services.
Telix doses first patient in Phase 3 LUTEON trial of TLX250-Tx for relapsed kidney cancer (ccRCC).
Neuronetics appoints Nir Naor as CFO to support its growth strategy across NeuroStar and Greenbrook.
Cosmos Health expands its Pharma Cell partnership to boost Sky Premium Life distribution across Albania.
Oncolytics' pelareorep gets FDA Fast Track for advanced anal cancer (SCAC) after prior therapy progression.
Merakris Therapeutics receives a $2.2 million NIH SBIR grant to advance MTX-001 for diabetic foot ulcer treatment.
Akari Therapeutics partners with Whitehawk Therapeutics to combine PH1 and TOP1i payload technologies for next-generation ADC cancer treatments.
IMUNON reports positive Phase 2 MRD trial results for IMNN-001, showing reduced residual disease in advanced ovarian cancer patients.
Revagenix promotes Peter Smith, Ph.D., to Chief Scientific Officer to lead Rev-56 development and expand its pipeline.
NeuroSigma launches its second-generation Monarch eTNS System, an FDA-cleared non-drug treatment for pediatric ADHD, in the U.S.
Myriad Genetics launches FirstGene, combining fetal, carrier, and RhD prenatal genetic screening into a single maternal blood test.
Sanofi announces major Executive Committee changes effective September 2026 as it enters its next growth phase.
AiM Medical Robotics names Andrew Aberdale President and CFO to lead its commercial expansion.
LB Pharmaceuticals accelerates its Phase 3 NOVA-2 trial, now expecting LB-102 topline schizophrenia data in early 2027.
Unnatural Products appoints Dr. Neera Ravindran as CFO to guide capital strategy for its macrocyclic peptide therapeutics platform.
Exubrion Therapeutics promotes Gregory Taglialatela to Chief Commercial Officer to expand Synovetin OA access in veterinary markets.
Akari Therapeutics CEO discusses the Whitehawk collaboration and dual-payload ADC strategy in a Virtual Investor interview.
Spryte Medical enrolls first patients in its FDA-approved INSYTE trial evaluating the nOCT Imaging System for intracranial aneurysms.
NexTel Medical expands its acquisition to include Island 40 Group and its full subsidiary portfolio in a $12.75 million deal.
FDA accepts Revolution Medicines' NDA for daraxonrasib, its RAS(ON) inhibitor for previously treated metastatic pancreatic cancer.
Serina Therapeutics appoints Trevi Therapeutics executive Dr. Farrell Simon to its Board to support SER-252 and POZ Platform growth.
VERAXA Biotech appoints Dr. Christoph Erkel as Chief Scientific Officer to lead its BiTAC cancer therapy platform.
Inhibikase Therapeutics' IKT-001 receives FDA Orphan Drug Designation for treating pulmonary arterial hypertension.
Atsena Therapeutics' ATSN-101 and ATSN-201 gene therapies receive EMA orphan designation for rare inherited retinal diseases.
Intelligent Bio Solutions completes cybersecurity review, staying on track for its FDA 510(k) submission in the second half of 2026.
Precision Neuroscience appoints BCI pioneer Dr. John Donoghue as Scientific Advisor to guide its Layer 7 brain-computer interface platform.
China's NMPA approves Nuvectis Pharma's ciprocopan, the first oral Factor B inhibitor, for treatment-naive PNH patients.
Longeveron elects Dr. Deborah Ascheim to its Board of Directors to support development of laromestrocel for pediatric heart disease.
Jyong Biotech reaffirms its global licensing strategy for Botreso, its botanical drug candidate for benign prostatic hyperplasia.
Idorsia partners with Jamjoom Pharma to bring its insomnia treatment QUVIVIQ to Saudi Arabia and the Levant region.
Ascentage Pharma CEO Dr. Dajun Yang is ranked No. 3 among small molecule leaders in The Medicine Maker Power List 2026.
argenx agrees to acquire Forte Biosciences for $2.2 billion, adding FB102 to expand its autoimmune disease pipeline.
ARCpoint's Board reviews strategic recommendations after Interim CEO Peter Kendall steps down, as the search for a permanent CEO begins
Drug Safety Symposium 2026 India Chapter concludes, bringing together PV leaders to advance AI, regulation and patient safety.
Inspire Medical Systems appoints AtriCure CEO Michael H. Carrel to its Board to support its long-term growth strategy.
CytomX Therapeutics appoints oncology expert Dr. Charles Fuchs to its Board to support its PROBODY cancer therapy pipeline.
Spero Therapeutics appoints Dr. Debra Jeske Zack as Chief Medical Officer to lead clinical development of its SP001 immunology program.
Kyverna Therapeutics and ElevateBio sign a manufacturing agreement to support the commercial launch of miv-cel for autoimmune diseases.
Lexicon Pharmaceuticals completes enrollment in its Phase 3 SONATA-HCM trial of sotagliflozin for hypertrophic cardiomyopathy.
FDA clears Medicus Pharma to begin its Phase 2b SkinJect trial treating basal cell carcinomas in Gorlin Syndrome patients.
Cato Healthcare Supply appoints Ryan F. Zackon as President and CEO to lead its healthcare supply chain growth strategy.
Revagenix doses first participant in its Phase 1 trial of Rev-56, an inhaled therapy for non-cystic fibrosis bronchiectasis.
Idorsia partners with Jamjoom Pharma to commercialize QUVIVIQ for insomnia in Saudi Arabia and the Levant, expanding its global market reach.
Sone-Ve shows significant overall survival benefits in advanced CLDN18.2-positive gastric cancers in the Phase III CLARITY-Gastric01 trial.
Ultomiris misses the Phase III primary endpoint in adult HSCT-TMA, while paediatric data support meaningful survival benefits.
Veru completes enrollment in its Phase 2b PLATEAU trial evaluating enobosarm with semaglutide to preserve muscle and improve weight loss in older adults.
Decoy Therapeutics' antiviral candidate shows activity against Ebola and Lassa fever viruses, prompting a new programme targeting filoviruses.
BioMarin and n-Lorem partner to develop an ASO therapy targeting ReNU syndrome, a rare genetic disorder affecting an estimated 100,000 people globally.
Micron Biomedical receives a $4.5 million NIAID contract to develop a thermostable dissolvable microarray treatment for radiation injury.
AGC Biologics secures a multi-year deal worth hundreds of millions, reserving capacity at its new Yokohama plant.
STRATA Skin Sciences appoints Erica Jordan CEO to lead its next phase of commercial growth.
Relmada names Bipin Dalmia Chief Business Officer as its NMIBC therapy NDV-01 advances.
Bicara Therapeutics appoints Jeremy Bender and Christy Oliger to its Board as Mazumdar-Shaw retires.
Cato Healthcare Supply strengthens leadership with four new executive appointments across key functions.
Starget Pharma adds oncology experts Oliver Sartor and Michael Hofman to its Scientific Advisory Board.
Pluri's Cellav secures UK registration for Regenativo+, clearing its commercial launch in UK aesthetics.
Nasus Pharma names Brendan O'Grady CEO to drive commercial growth ahead of NS002's pivotal trial.
Basilea secures an additional $30M from BARDA for its Phase 3 antifungal therapy fosmanogepix.
Perspective Therapeutics receives EU orphan designation for [²¹²Pb]VMT-α-NET, a potential radiopharmaceutical treatment for GEP-NETs.
Grace Therapeutics receives FDA meeting minutes and advances dual-source manufacturing plans to address GTx-104 regulatory requirements.
Neuronetics opens Greenbrook's largest mental health centre in Maryland to expand advanced psychiatric care and accelerate clinical innovation.
NurExone appoints David Stolick to its Board, bringing extensive finance, M&A and healthcare leadership experience to the exosome therapy company.
Alamar Biosciences launches its broadest NULISAseq Immune 340 Panel to advance immune profiling and research across cancer, aging and chronic diseases.
AscellaHealth appoints Johanna van Nijkerk as VP of Business Development to support AscellaOne's growth and expand modern pharmacy benefit solutions.
Onco360 named specialty pharmacy partner for Rigel's VEPPANU, an FDA-approved therapy for ESR1-mutated advanced breast cancer.
Mesoblast reports US$115M first-year Ryoncil revenue and advances FDA trials expanding the GvHD cell therapy to adults and DMD.
European Commission approves Pfizer-BioNTech's XFG-adapted COVID-19 vaccine for ages 6 months+ for the 2026-2027 season.
60 Degrees Pharmaceuticals hits 24-patient enrolment for its Phase 2 tafenoquine trial in severe babesiosis; interim analysis due by October 2026.
MIMEDX to acquire Sanara MedTech for $35 per share in a $350M deal expanding its surgical regenerative medicine portfolio.
Ipsen appoints Catherine Bradley as an independent director and Audit Committee Chair, bringing 30+ years in finance and governance.
Acentra Health names Srini Surendranath Senior VP of Product and Solutions Management, a newly created product strategy role.
Clearmind reports positive Phase I/II safety results for CMND-100, its drug candidate for Alcohol Use Disorder.
Capricor Therapeutics' Deramiocel gets a negative FDA advisory panel vote for DMD cardiomyopathy; the FDA's final decision on approval is still pending.
InspireMD appoints Kathleen Kennedy as Senior VP of Global Sales and Marketing to lead commercial strategy ahead of its planned U.S. CGuard launch.
Annexon secures a non-dilutive credit facility worth up to $200 million from Oxford Finance to support the commercial growth of its lead therapies.
Keros Therapeutics earns a $20 million milestone from Takeda after dosing the first patient in its Phase 3 ELRiSE MDS trial for elritercept therapy.
Abivax aligns with the FDA on its NDA submission strategy for obefazimod, remaining on track for a 2026 filing to treat ulcerative colitis.
Replimune Group wins a 10-3 FDA advisory committee vote backing its RP1 melanoma therapy, ahead of the agency's August 2, 2026 decision date.
Seosaph unveils PortiVix, the next evolution of SEOPRO, to help pharma organizations improve project execution, portfolio governance, and decision-making.
Vistagen names Dr. Douglas J. Williamson, ex-Acadia and QurAlis neuroscience leader, to its Board of Directors.
Profusa secures an option to acquire G3 Vision Labs' diagnostics business, projected to generate roughly $111 million in 2025 net revenue.
Rose Hill Life Sciences appoints biopharma veteran Jama Pitman as CEO to lead its psilocybin therapy development programs.
XORTX Therapeutics names financial services veteran Depesh Narotam as an independent director to strengthen its Board.
Novartis gains FDA approval for Pluvicto in earlier-stage PSMA-positive metastatic hormone-sensitive prostate cancer.
Ascentage Pharma appoints Dr. Faiçal Miyara as CBO and Jim Ziegler as CCO to lead global business and commercial growth.
Novo Nordisk's cardiovascular drug ziltivekimab misses its primary endpoint in a Phase III trial, shares fall 7.3%.
AstraZeneca and Bristol Myers Squibb reportedly held early talks on a merger worth nearly $400 billion.
Novo Nordisk's ziltivekimab fails its cardiovascular trial, raising pressure to diversify beyond obesity and diabetes.
Altimmune starts its global Phase 3 PERFORMA trial evaluating pemvidutide for MASH liver disease, following promising Phase 2b clinical results.
Achieve Life Sciences appoints Ronald Dadino as SVP of CMC/Supply Chain and Gloria Cosgrove as SVP of Quality as cytisinicline nears U.S. launch.
Cue Biopharma appoints James Ahlers as Chief Financial Officer to support clinical growth and upcoming CUE-221 and CSU development milestones.
AIM ImmunoTech completes final patient dosing in its Phase 2 DURIPANC trial evaluating Ampligen for metastatic pancreatic cancer, ahead of schedule.
Codexis appoints David Butler to its Strategic Advisory Board to support growth in siRNA manufacturing and its enzymatic technology platform.
Mobia Medical appoints surgeon and healthcare executive Dr. Myriam Curet to its Board to support growth of its Vivistim stroke recovery therapy.
AEON Biopharma regains NYSE American listing compliance after a $13.6 million public offering strengthens its shareholders' equity position.
Teladoc Health appoints former Verisk executive Mark Anquillare to its Board to support growth, technology, and AI strategy initiatives.
Sanofi wins EU approval to expand MenQuadfi vaccine use to infants from six weeks of age, broadening protection against meningococcal disease.
Nurix Therapeutics enrolls the first patient in its Phase 3 DAYBreak CLL-306 trial evaluating bexobrutideg for relapsed or refractory CLL/SLL.
Chugai Pharmaceutical partners with the Japan Basketball Association to promote innovation, public health, and basketball development in Japan.
Decoy Therapeutics expands its patent portfolio with seven patent families covering its antiviral D-MAV technology and IMP³ACT design platform.
Acurx receives positive FDA feedback on ibezapolstat's Phase 3 plan, supporting a potential single-trial NDA pathway for CDI treatment.
Medicus Pharma appoints Dr. Faisal Mehmud as CEO of Antev to lead global development of Teverelix across multiple therapeutic indications.
Tonix advances TNX-4800 following FDA feedback, supporting a Phase 2 study of its monoclonal antibody to prevent seasonal Lyme disease.
Biocon gains EMA approval for its Malaysian insulin fill-finish facility and launches four U.S. biosimilars in Q1FY27, with biopharma revenue up 17% year-on-year.
FibroBiologics secures EPO patent EP 3043825 B1 for Sox9-based fibroblast-to-chondrocyte gene therapy, covering viral and non-viral vectors across EPC markets.
Fresenius Kabi recalls Morphine Sulfate Simplist lot after Dilaudid syringes found in morphine packaging. QA directors should review label reconciliation controls.
Victory Medical Center Pharmacy recalls compounded glutathione 200 mg/mL vials over elevated endotoxin levels. Adverse events reported. QA implications for 503A compounders.
Biomea Fusion partners with University of Leicester on icovamenib-semaglutide Phase II obesity trial. Two T2D Phase II trials enrolling with 2027 data readouts.
FDA approves Takeda's Orzeyful (oveporexton) for narcolepsy type 1. DEA scheduling pending before launch. CYP3A labeling and regulatory pathway analysis.
Aurobindo Pharma posts 16.3% revenue growth to Rs 9,150 crore in Q1 FY27. EBITDA margin expands 60 bps to 21.0% as US generics and injectables capacity scales.
Rhythm's Phase 2 trial shows RM-718 reduced BMI by 11.6% in acquired hypothalamic obesity patients, with encouraging safety and tolerability results.
Autonomix secured a U.S. patent for catheter-based neural mapping technology designed to enable precision cancer treatment and targeted nerve modulation.
Veru receives a USPTO Notice of Allowance for a patent covering enobosarm with semaglutide to improve weight-loss outcomes and preserve lean muscle mass.
BARDA awarded Basilea an additional $5.4M to develop its oral antibiotic for complicated UTIs, bringing total funding for the program to $30.8M.
Amplia Therapeutics partners with Eli Lilly on a Phase 1b/2b trial combining narmafotinib with olomorasib for advanced non-small cell lung cancer.
Capra Biosciences secures additional ASPR funding, bringing total support to $17 million, to expand domestic manufacturing of critical APIs.
Silexion Therapeutics reports new preclinical data showing SIL204 may boost immune response to KRAS-driven cancers, supporting checkpoint combos.
ClinNEXUS appoints John Stamatopoulos as Chief Growth Officer to drive strategic expansion of its AI-powered ClinxOS healthcare platform.
Applied Biologics begins its AATB reaccreditation process, marking nearly a decade of continuous tissue banking accreditation for XWRAP.
IQVIA partners with Medera to accelerate cardiac gene therapy development and human-based drug discovery through Sardocor and Novoheart.
Editas Medicine appoints cardiovascular genetics expert Dr. Patrick Ellinor to its Board as it advances its gene editing pipeline including EDIT-401.
Sight Sciences receives FDA clearance for its OMNI Ultra Surgical System, an implant-free MIGS device for treating open-angle glaucoma.
3PBIOVIAN establishes GMP manufacturing protocols for AI-identified TCR candidates in the €1.6M PITÁGORAS personalized immunotherapy project in Navarra.
FDA signals enforcement action on unapproved DTE products used by 1.5M patients, issuing compliance and NDA development guidance for manufacturers.
Propanc Biopharma reports >90% tumor growth inhibition for PRP in PDAC preclinical models. GMP production targeted late 2026 ahead of Phase 1b first-in-human study.
Ascendis Pharma reports COACH Week 78 combination therapy data, completes reACHin Trial enrollment for infants, and records 170+ YUVIWEL U.S. enrollments.
Lexicon Pharmaceuticals targets Q4 2026 for ZYNQUISTA NDA resubmission in T1D as STENO1 safety data approach FDA-specified thresholds. SONATA-HCM enrollment complete.
Allergan Aesthetics submits sNDA to FDA for BOTOX Cosmetic jawline indication. Key regulatory, QA, and labeling implications for pharma operations teams.
Tarsus Pharmaceuticals acquires Alkeus and Phase 3 gildeuretinol for Stargardt disease, triggering GMP scale-up and NDA strategy work in a rare retinal indication.
Harrow's acquisition of TYRVAYA from Viatris spans U.S., China, and Taiwan approvals plus pending MAAs, raising CMC transfer and GMP compliance obligations.
Priovant enrolls first patients in BEACON+ Phase 3 brepocitinib trial for cutaneous sarcoidosis. FDA Breakthrough Designation accelerates CMC and process validation timelines.
Roivant targets September 2026 brepocitinib launch in dermatomyositis. QA directors and plant heads face compressed batch release and GMP documentation timelines.
Lantheus and Curium's $8B merger creates a 70-country radiopharmaceutical network. Key GMP harmonisation and regulatory filing implications for QA and plant heads.
Realbotix LLC, Onconetix's pending acquisition target, secures a humanoid robot appearance on an Emmy-awarded streaming series as healthcare deployments continue.
FDA clears Moderna's MFLUSIVA under BLA 125869/0, the first mRNA influenza vaccine approved in the US. Key implications for biologics manufacturers and regulatory teams.
Phio Pharmaceuticals initiates commercial-scale API manufacturing for siRNA candidate PH-762 and plans an FDA meeting in Q3 2026 on next-phase clinical trial design.
FDA Orange Book data files provide monthly-updated TE codes, patent records, and RLD designations via ZIP and openFDA API. Essential for ANDA and generic drug strategy.
FDA grants Aclaris Therapeutics Fast Track Designation for modzatinib in moderate to severe lichen planus, enabling rolling NDA review ahead of Q4 2026 Phase 2b trial.
Cognition Therapeutics confirms FDA design discussions for zervimesine Phase 3 in DLB psychosis. Endpoint alignment pending; mid-2027 trial start targeted with revised tablet formulation.
Zentalis Pharmaceuticals confirms FDA alignment on azenosertib 400mg dose after Type D meeting, keeping accelerated approval pathway intact ahead of 1H 2027 DENALI readout.
FDA grants Replimune accelerated approval for Tudriqev (vusolimogene oderparepvec-wtpg) plus nivolumab in unresectable melanoma. Confirmatory trials required.
FDA closes Warning Letter 320-25-30 for Global Calcium Pvt. Limited. What the closure language means for GMP compliance and future inspection risk.
FDA issued a warning letter to Global Calcium Pvt. Limited over falsified API batch records and deleted electronic files during a 2024 CGMP inspection in Tamil Nadu.
FDA grants accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg) for anti-PD-1 refractory melanoma. Key CMC, potency, and CBER post-approval implications for manufacturers.
FDA CBER's OTP outlined CMC expectations for gene therapy BLA submissions in a June 2024 town hall, flagging comparability and stability data as key deficiency areas.
Emcure Pharma Q1 FY2026 revenue rises 23% to Rs 2,580 crore. PAT up 36.2% with margin expansion of 110 bps. Key read for CDMO and generics supply chain leads.
Kiora Pharmaceuticals advances KIO-301 into higher-dose Phase 2 cohort with Théa and Senju partnerships framing a potential global Phase 3 registration study.
Sanofi names Archana Subramanya Head of R&D India Hub. The former GSK Global Regulatory Centers lead brings multi-jurisdictional GMP and ICH expertise to the role.